Dimensional Fund Advisors LP raised its stake in TESARO, Inc. (NASDAQ:TSRO) by 0.4% during the first quarter, Holdings Channel reports. The fund owned 90,684 shares of the biopharmaceutical company’s stock after buying an additional 363 shares during the period. Dimensional Fund Advisors LP’s holdings in TESARO were worth $13,954,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. State Board of Administration of Florida Retirement System raised its position in shares of TESARO by 0.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock valued at $2,576,000 after buying an additional 150 shares during the last quarter. Trellus Management Company LLC acquired a new position in shares of TESARO during the first quarter valued at approximately $1,154,000. Tocqueville Asset Management L.P. raised its position in shares of TESARO by 11.1% in the first quarter. Tocqueville Asset Management L.P. now owns 62,055 shares of the biopharmaceutical company’s stock valued at $9,548,000 after buying an additional 6,225 shares during the last quarter. Whittier Trust Co. raised its position in shares of TESARO by 4.8% in the first quarter. Whittier Trust Co. now owns 11,186 shares of the biopharmaceutical company’s stock valued at $1,721,000 after buying an additional 515 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of TESARO by 3.9% in the first quarter. Russell Investments Group Ltd. now owns 25,329 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 954 shares during the last quarter.
TESARO, Inc. (NASDAQ:TSRO) traded down 0.954% during trading on Wednesday, hitting $112.912. The stock had a trading volume of 102,175 shares. TESARO, Inc. has a 12 month low of $83.26 and a 12 month high of $192.94. The stock’s market cap is $6.12 billion. The stock has a 50 day moving average price of $128.57 and a 200-day moving average price of $148.68.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.30. The company had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. TESARO’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.28) earnings per share. On average, equities analysts predict that TESARO, Inc. will post ($8.74) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “TESARO, Inc. (TSRO) Stake Raised by Dimensional Fund Advisors LP” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2017/08/16/tesaro-inc-tsro-stake-raised-by-dimensional-fund-advisors-lp.html.
TSRO has been the subject of a number of recent research reports. Oppenheimer Holdings, Inc. initiated coverage on TESARO in a research report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 target price for the company. Cann restated an “outperform” rating on shares of TESARO in a research report on Wednesday, May 24th. Credit Suisse Group set a $198.00 target price on TESARO and gave the stock a “buy” rating in a research report on Monday, June 5th. FBR & Co dropped their target price on TESARO from $200.00 to $195.00 and set a “mkt perform” rating for the company in a research report on Monday, June 5th. Finally, Wedbush upgraded TESARO to an “outperform” rating and set a $168.00 target price for the company in a research report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $176.35.
In other news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now directly owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 34.60% of the stock is owned by company insiders.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).
What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.